Stock AXIM AXIM BIOTECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Market Closed - OTC Markets
Other stock markets
 01:26:54 03/05/2024 am IST 		5-day change 1st Jan Change
0.0122 USD -18.67% Intraday chart for AXIM Biotechnologies, Inc. +11.93% -35.79%
16/04 AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
15/03 AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
AXIM Biotechnologies, Inc. Appoints Kurt Phinney as Chief Operating Officer
AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
AXIM Biotechnologies, Inc. Auditor Raises 'Going Concern' Doubt
AXIM Biotechnologies, Inc. Files Patent on Fentanyl Neutralizing Antibody Test, Applies for Drug Enforcement Administration License to Work with Controlled Substance
AXIM Biotechnologies, Inc. Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test and Files Provisional Patent
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
AXIM Biotechnologies, Inc. Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch
Axim® Biotechnologies Signs Exclusive Global Commercialization Agreement with Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions
Insider Buy: Axim Biotechnologies
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
AXIM Biotechnologies, Inc. Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AXIM Stock
  4. News AXIM Biotechnologies, Inc.
  5. Other languages